Clermont, Bosley LLC was created to help pharma/biotech clients increase R&D yield, with collaborations that use proven predictive modeling techniques to support better translational and clinical decisions.
There are higher barriers to new drug approvals than ever before. For illnesses with approved treatments, new drugs must be significantly more effective and safer. On the other hand,today’s unmet medical needs involve incredibly complex diseases. To address this, incredibly large and complex data sets have been generated. In the face of higher bars, more complex diseases, and overwhelmingly large data sets, R&D productivity (new NMEs and BLAs) has dropped. How can scientists and executives reverse the trend and increase the productivity of their programs?
At Clermont, Bosley LLC, we have experience in helping clients support more efficient drug development using a physiological, mechanistic modeling approach. We use our PhysioMech™ models to scientifically integrate a broad range of data to yield deeper insights that support better decisions. This approach allows our clients to:
Support better program decisions by using and understanding more data
PhysioMech models integrate a broader range of data and knowledge scientifically
Improve R&D return with better experimental/trial design using quantitative outcome estimates
PhysioMech simulations allow design of experiments/trials that deliver more clarity and insight
Enhance R&D organizational effectiveness
PhysioMech model collaborations enhance communication and often help build consensus
We know that Pharma R&D decisions can be difficult. Clermont, Bosley LLC’s only job is to help our clients succeed by providing better insight and support for those decisions. Please contact us to explore how we can work together to enhance your program’s success.
There are higher barriers to new drug approvals than ever before. For illnesses with approved treatments, new drugs must be significantly more effective and safer. On the other hand,today’s unmet medical needs involve incredibly complex diseases. To address this, incredibly large and complex data sets have been generated. In the face of higher bars, more complex diseases, and overwhelmingly large data sets, R&D productivity (new NMEs and BLAs) has dropped. How can scientists and executives reverse the trend and increase the productivity of their programs?
At Clermont, Bosley LLC, we have experience in helping clients support more efficient drug development using a physiological, mechanistic modeling approach. We use our PhysioMech™ models to scientifically integrate a broad range of data to yield deeper insights that support better decisions. This approach allows our clients to:
Support better program decisions by using and understanding more data
PhysioMech models integrate a broader range of data and knowledge scientifically
Improve R&D return with better experimental/trial design using quantitative outcome estimates
PhysioMech simulations allow design of experiments/trials that deliver more clarity and insight
Enhance R&D organizational effectiveness
PhysioMech model collaborations enhance communication and often help build consensus
We know that Pharma R&D decisions can be difficult. Clermont, Bosley LLC’s only job is to help our clients succeed by providing better insight and support for those decisions. Please contact us to explore how we can work together to enhance your program’s success.
For more information, please write to us at info@clerbos.com